Btk

Bruton tyrosine kinase

Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca^{2+} stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Btk Inhibitors

(Rac)-IBT6A

Cat. No.: HY-13036

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-IBT6A hydrochloride

Cat. No.: HY-13036C

(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Sunvozertinib

((S)-DZD9008)

Cat. No.: HY-132842A

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against **EGFR** exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC_{50}=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(±)-Zanubrutinib

((±)-BGB-3111)

Cat. No.: HY-101474

(±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available **Bruton's tyrosine kinase (Btk)** inhibitor.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Acalabrutinib

(ACP-196)

Cat. No.: HY-17600

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation **BTK** inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Acalabrutinib-d4

(ACP-196-d4)

Cat. No.: HY-17600S

Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

ACP-5862

Cat. No.: HY-135334

ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an **IC_{50}** of 5.0 nM for **Bruton tyrosine kinase (BTK)**. ACP5862 is a weak timedependent inactivator of **CYP3A4** and **CYP2C8**.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

ACP-5862-d4

Cat. No.: HY-135334S

ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

ARQ 531

(MK-1026)

Cat. No.: HY-112215

ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton's Tyrosine Kinase (**BTK**), with **IC_{50}s** of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.



Purity: 99.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-1763

Cat. No.: HY-132877

AS-1763 is a potent, selective, noncovalent, and orally available inhibitor of **Bruton's tyrosine kinase** (**IC_{50}** = 0.85 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Atuzabrutinib

(SAR 444727; PRN473) Cat. No.: HY-132808

Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of **Btk (Bruton's tyrosine kinase)** inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avitinib

(Abivertinib; AC0010) Cat. No.: HY-19816

Avitinib (AC0010) is an irreversible, mutant-selective **EGFR** inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCPyr

Cat. No.: HY-142621

BCPyr is a new candidate **BTK** degrader (DC_{50} = 800 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIIB068

Cat. No.: HY-131342

BIIB068 is a potent, selective, reversible and orally active **BTK** inhibitor with an IC_{50} of 1 nM and a K_d of 0.3 nM. BIIB068 shows more >400-fold selective for **BTK** than other kinases. BIIB068 has the potential for autoimmune diseases research.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIIB091

Cat. No.: HY-139984

BIIB091 is a highly selective, reversible **BTK** inhibitor for treating autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BLK-IN-1

Cat. No.: HY-144283

BLK-IN-1 (compound 1) is a selective and covalent inhibitor of **B-Lymphoid tyrosine kinase (BLK)** and **BTK**, with IC_{50}s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLK-IN-2

Cat. No.: HY-144288

BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of **B-Lymphoid tyrosine kinase (BLK)**, with an IC_{50} of 5.9 nM. BLK-IN-2 also inhibits **BTK** (IC_{50}=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-935177

Cat. No.: HY-101793

BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (**Btk**) with an IC_{50} of 3 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986142

Cat. No.: HY-101856

BMS-986142 is a potent and highly selective reversible inhibitor of **Bruton's tyrosine kinase** (**BTK**) with an IC_{50} of 0.5 nM.



Purity: 99.53%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986143

Cat. No.: HY-145373

BMS-986143 is an orally active, reversible **BTK** inhibitor with an IC_{50} of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC_{50}s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMX-IN-1

(BMX kinase inhibitor) Cat. No.: HY-80002

BMX-IN-1 is a selective, irreversible inhibitor of **bone marrow tyrosine kinase on chromosome X (BMX)** that targets Cys^{496} in the BMX ATP binding domain with an IC_{50} of 8 nM, also targets the related Bruton's tyrosine kinase **(BTK)** with an IC_{50} value of 10.4 nM, but is more...



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Branebrutinib

(BMS-986195) Cat. No.: HY-112161

Branebrutinib (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase **(BTK)**, with an IC_{50} of 0.1 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BTK IN-1

(SNS062 analog) Cat. No.: HY-101941

BTK IN-1 (SNS062 analog) is a potent **BTK** inhibitor, with an IC_{50} of <100 nM.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTK inhibitor 10

Cat. No.: HY-125997

BTK inhibitor 10 is a potent and orally active **Bruton kinase (BTK)** inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 13

Cat. No.: HY-130255

BTK inhibitor 13 (compound 8) is a potent and selective **Bruton's tyrosine kinase (BTK)** inhibitor with an IC_{50} of 1.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 17

Cat. No.: HY-131705

BTK inhibitor 17 is a potent and orally active irreversible **BTK** inhibitor with an IC_{50} of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 18

Cat. No.: HY-132196

BTK inhibitor 18 is a potent, selective,orally active and covalent **Btk** inhibitor with a IC_{50} of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 19

Cat. No.: HY-139881

BTK inhibitor 19 is a highly selective, covalent **BTK** inhibitor (IC_{50} = 2.7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Btk inhibitor 2

(BGB-3111 analog) Cat. No.: HY-101766

Btk inhibitor 2 (BGB-3111 analog) is a **Bruton's tyrosine kinase** (**BTK**) inhibitor extracted from patent US 20170224688 A1.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 20

Cat. No.: HY-143730

BTK inhibitor 20 is a potent **BTK** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-5

Cat. No.: HY-115876

BTK-IN-5 is a covalent **BTK** inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-6

Cat. No.: HY-142932

BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (**BTK**). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-7

Cat. No.: HY-143900

BTK-IN-7 is a potent and selective inhibitor of **BTK** (IC_{50}=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (**ITK** >250-fold, **EGFR** >2500-fold) and cellular levels(**ITK** >227-fold, **EGFR** 27-fold). BTK-IN-7 also has potent antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-8

Cat. No.: HY-145884

BTK-IN-8 is a potent selective peripheral covalent **BTK** inhibitor (IC_{50}=0.22 nM; K_d=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC_{50}=0.029 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK-IN-9

Cat. No.: HY-115944

BTK-IN-9 is a reversible **BTK** inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGI-1746

Cat. No.: HY-11999

CGI-1746 is a potent and highly selective inhibitor of the **Btk** with IC_{50} of 1.9 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHMFL-BTK-01

Cat. No.: HY-101521

CHMFL-BTK-01 (compound 9) is a highly selective irreversible **BTK** inhibitor, with an IC_{50} of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CNX-500

Cat. No.: HY-100338

CNX-500 is a probe consisting of a covalent **Btk** inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against **Btk** (IC_{50} of 0.5 nM) and the ability to form a covalent bond with **Btk**.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CNX-774

Cat. No.: HY-13943

CNX-774 is an orally active, irreversible and selective **BTK** inhibitor, with an IC_{50} of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CTA056

Cat. No.: HY-110113

CTA056 is an **ITK** (IL-2-inducible T-cell kinase) inhibitor with an IC_{50} of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydrodiol-Ibrutinib

(PCI-45227)

Cat. No.: HY-100659

Dihydrodiol-Ibrutinib (PCI-45227) is a dihydrodiol active **metabolite** of Ibrutinib (HY-10997), has inhibitory activity towards **BTK** approximately 15 times lower than that of ibrutinib.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg

Edralbrutinib

(TG-1701)

Cat. No.: HY-137438

Edralbrutinib (TG-1701) is a potent **BTK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elsubrutinib

(ABBV-105)

Cat. No.: HY-109143

Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (**BTK**) inhibitorThe IC_{50} of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fenebrutinib

(GDC-0853)

Cat. No.: HY-19834

Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (**Btk**) inhibitor with K_is of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants.



Purity: 99.83%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

G-744

Cat. No.: HY-102036

G-744 is a highly potent, selective and orally active **Btk** inhibitor with an IC_{50} of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GDC-0834

Cat. No.: HY-15427

GDC-0834 is a potent and selective **BTK** inhibitor. GDC-0834 inhibits BTK with an in vitro IC_{50} of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC_{50} of 1.1 and 5.6 μM in mouse and rat, respectively.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0834 Racemate

Cat. No.: HY-15427A

GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0834 S-enantiomer

Cat. No.: HY-15427B

GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor.



Purity: 95.11%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

Ibrutinib

(PCI-32765) Cat. No.: HY-10997

Ibrutinib (PCI-32765) is a selective, irreversible **Btk** inhibitor with an **IC_{50}** of 0.5 nM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Ibrutinib deacryloylpiperidine

(IBT4A) Cat. No.: HY-78727

Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Ibrutinib dimer

Cat. No.: HY-136113

Ibrutinib dimer is a Dimer of Ibrutinib. Ibrutinib dimer is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibrutinib Racemate

(PCI-32765 Racemate) Cat. No.: HY-10997A

Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible **Btk** inhibitor with **IC_{50}** value of 0.5 nM.



Purity: 95.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ibrutinib-biotin

Cat. No.: HY-100342

Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an **IC_{50}** of 0.755-1.02 nM for **BTK**.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ibrutinib-d5

(PCI-32765-d5) Cat. No.: HY-10997S

Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IBT6A

Cat. No.: HY-13036A

IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IBT6A hydrochloride

Cat. No.: HY-13036B

IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC_{50} of 0.5 nM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JAK3/BTK-IN-1

Cat. No.: HY-143716

JAK3/BTK-IN-1 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-2

Cat. No.: HY-143717

JAK3/BTK-IN-2 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-3

Cat. No.: HY-143718

JAK3/BTK-IN-3 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-4

Cat. No.: HY-143719

JAK3/BTK-IN-4 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-5

Cat. No.: HY-143720

JAK3/BTK-IN-5 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LFM-A13

Cat. No.: HY-18009

LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC_{50}s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Luxeptinib

(CG-806)

Cat. No.: HY-139535

Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent **pan-FLT3/pan-BTK** inhibitor. Luxeptinib induces cell cycle arrest, **apoptosis** or **autophagy** in acute myeloid leukemia cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MT-802

Cat. No.: HY-122562

MT-802 is a potent **BTK** degrader based on **Cereblon** ligand, with a DC_{50} of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-piperidine Ibrutinib hydrochloride

Cat. No.: HY-130983

N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent **BTK** inhibitor with IC_{50}s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively.



Purity: 95.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-4059 analog

Cat. No.: HY-18951

ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orelabrutinib

(ICP-022)

Cat. No.: HY-129390

Orelabrutinib (ICP-022) is a potent, orally active, and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor with potential antineoplastic activity.



Purity: 99.90%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCI 29732

Cat. No.: HY-18010

PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i^{app} values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCI-33380

Cat. No.: HY-100335

PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase **(BTK)** inhibitor (fluorescent probe).



Purity: 95.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06250112

Cat. No.: HY-117900

PF-06250112 is a potent, highly selective, orally bioavailable **BTK** inhibitor with an IC_{50} of 0.5 nM, shows inhibitory effect toward **BMX nonreceptor tyrosine kinase** and **TEC** with IC_{50}s of 0.9 nM and 1.2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pirtobrutinib

(LOXO-305)

Cat. No.: HY-131328

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation **BTK** inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models.



Purity: 99.88%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Poseltinib

(HM71224; LY3337641)

Cat. No.: HY-109010

Poseltinib, an orally active, selective and irreversible **Bruton's tyrosine kinase (BTK)** inhibitor (IC_{50} =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively.



Purity: 98.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

QL-X-138

Cat. No.: HY-124645

QL-X-138 is a potent and selective **BTK/MNK dual kinase** inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC_{50}s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QL47

Cat. No.: HY-80003

QL47, a broad-spectrum **antiviral** agent, inhibits dengue virus and other RNA viruses. QL47 selectively inhibits eukaryotic translation. QL47 is a potent covalent inhibitor of **BTK** with an IC_{50} of 7 nM.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Remibrutinib

Cat. No.: HY-128757

Remibrutinib, is a potent and orally active **bruton tyrosine kinase (BTK)** inhibitor with an IC_{50} value of 1 nM. Remibrutinib inhibits BTK activity with an IC_{50} value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.



Purity: 99.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RET-IN-14

Cat. No.: HY-144170

RET-IN-14 (compound 49) is a potent **RET** inhibitor with IC_{50}s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rilzabrutinib

(PRN1008)

Cat. No.: HY-112166

Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton's Tyrosine Kinase **(BTK)**, with an IC_{50} of 1.3 nM.



Purity: 98.22%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RN486

Cat. No.: HY-18018

RN486 is a potent, selective and orally active **Btk** inhibitor with an IC_{50} of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SJF620

Cat. No.: HY-133137

SJF620 is a PROTAC connected by ligands for **Cereblon** and **Btk** with a DC_{50} of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SJF620 hydrochloride

Cat. No.: HY-133137A

SJF620 hydrochloride is a PROTAC connected by ligands for **Cereblon** and **Btk** with a DC_{50} of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Spebrutinib

(AVL-292; CC-292)

Cat. No.: HY-18012

Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC_{50} of 0.5 nM.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Spebrutinib besylate

(AVL-292 benzenesulfonate; CC-292 besylate)

Cat. No.: HY-18012A

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of **Btk** kinase activity (IC_{50}<0.5 nM, K_{inact}/K_i=7.69×10^4 M^{-1}s^{-1}) in biochemical assays.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Sunvozertinib

(DZD9008)

Cat. No.: HY-132842

Sunvozertinib (DZD9008) is a potent **ErbBs** (EGFR, Her2, especially mutant forms) and **BTK** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-020

Cat. No.: HY-132879

TAK-020 is a covalent **Btk** inhibitor, which becomes the clinical candidate.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terreic acid

Cat. No.: HY-110013

Terreic acid, a quinone epoxide **antibiotic**, acts as an effective **Btk** inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tirabrutinib

(ONO-4059; GS-4059)

Cat. No.: HY-15771

Tirabrutinib (ONO-4059) is a selective and novel inhibitor of BTK with IC_{50} 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tirabrutinib hydrochloride

(ONO-4059 hydrochloride; GS-4059 hydrochloride)

Cat. No.: HY-15771A

Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC_{50} 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TL-895

Cat. No.: HY-139481

TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible **BTK** inhibitor with an IC_{50} and a K_i of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tolebrutinib

(SAR442168; PRN2246) Cat. No.: HY-109192

Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of **Bruton tyrosine kinase (BTK)**, with IC_{50}s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively.



Purity: 98.96%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Vecabrutinib

(SNS-062) Cat. No.: HY-109078

Vecabrutinib (SNS-062) is a potent, noncovalent **BTK** and **ITK** inhibitor, with K_d values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC_{50} of 24 nM for **ITK**.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XMU-MP-3

Cat. No.: HY-136531

XMU-MP-3 is a potent non-covalent **BTK** inhibitor with IC_{50}s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation in the presence of 10 μM ATP, respectively. XMU-MP-3 also induces **apoptosis**.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Zanubrutinib

(BGB-3111) Cat. No.: HY-101474A

Zanubrutinib (BGB-3111) is a selective **Bruton tyrosine kinase** (**Btk**) inhibitor.



Purity: 99.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Zanubrutinib D5

(BGB-3111 D5) Cat. No.: HY-101474S

Zanubrutinib D5 (BGB-3111 D5) is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg